• By ICR Secretariat
  • Posted Wednesday, April 22, 2020

A guide to clinical trials disrupted by the coronavirus pandemic


The coronavirus has upended the globe. Cities and countries have enacted shelter-in-place policies, shuttering businesses while canceling school and other events. Many companies have sent their employees home.

All are measures taken in the name of “social distancing,” the best way of keeping the virus at bay until therapies and vaccines are available to stop it.

Much attention, and rightly so, is focused on the drugs the biopharma industry is developing to treat COVID-19. But those efforts could disguise a cost to public health, too, in the form of stalled progress on experimental medicines for other diseases.